These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 33685075)

  • 21. [Guidelines for the prevention and treatment of hepatitis C (2019 version)].
    ;
    Zhonghua Gan Zang Bing Za Zhi; 2019 Dec; 27(12):962-979. PubMed ID: 31941258
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnosis and management of hepatitis C.
    Vine LJ; Sieberhagen C; Cramp ME
    Br J Hosp Med (Lond); 2015 Nov; 76(11):625-30. PubMed ID: 26551491
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges.
    Zeng H; Li L; Hou Z; Zhang Y; Tang Z; Liu S
    Int J Med Sci; 2020; 17(7):892-902. PubMed ID: 32308542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis C virus virology and new treatment targets.
    Meier V; Ramadori G
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):329-50. PubMed ID: 19344246
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic testing for hepatitis C.
    Carithers RL; Marquardt A; Gretch DR
    Semin Liver Dis; 2000; 20(2):159-71. PubMed ID: 10946421
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis C elimination: challenges with under-diagnosis and under-treatment.
    Terrault NA
    F1000Res; 2019; 8():. PubMed ID: 30687501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. REtrieval And cure of Chronic Hepatitis C (REACH): Results of micro-elimination in the Utrecht province.
    Kracht PAM; Arends JE; van Erpecum KJ; Thijsen SFT; Vlaminckx BJM; Weersink AJL; Wensing AMJ; Deege MPH; Dimmendaal M; Stadhouders PHGM; Friederich PW; Verhagen MAMT; Boland GJ; Hoepelman AIM
    Liver Int; 2019 Mar; 39(3):455-462. PubMed ID: 30204289
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Hepatitis C].
    Moradpour D; Blum HE
    Ther Umsch; 2004 Aug; 61(8):493-8. PubMed ID: 15457965
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Therapeutic update in hepatitis C].
    Devesa MJ; Cuenca F; Izquierdo S; Sánchez-Pobre P; Ladero JM; López-Alonso G; Díaz-Rubio M; Rey E
    Rev Esp Quimioter; 2015 Sep; 28 Suppl 1():48-51. PubMed ID: 26365735
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Directly acting antivirals against hepatitis C virus.
    Soriano V; Vispo E; Poveda E; Labarga P; Martin-Carbonero L; Fernandez-Montero JV; Barreiro P
    J Antimicrob Chemother; 2011 Aug; 66(8):1673-86. PubMed ID: 21652618
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Guideline for the prevention and treatment of hepatitis C (2022 version)].
    ;
    Zhonghua Gan Zang Bing Za Zhi; 2022 Dec; 30(12):1332-1348. PubMed ID: 36891719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiviral drugs have made hepatitis C eminently treatable.
    Ladika S
    Manag Care; 2018 Nov; 27(11):23-30. PubMed ID: 30620304
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment of chronic viral hepatitis C with direct acting antiviral agent: review].
    Malov VA; Ubeeva EA; Ubeeva IP; Nikolaev SM; Umbetova KT
    Ter Arkh; 2019 Nov; 91(11):86-89. PubMed ID: 32598617
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Direct-acting antiviral treatments in Australia for children with chronic hepatitis C virus infection.
    Eldredge JA; Stormon MO; Clark JE; Nightingale S; McMullan B; Andersen B; Travers C; Hardikar W
    Med J Aust; 2023 Mar; 218(5):229-230. PubMed ID: 36794442
    [No Abstract]   [Full Text] [Related]  

  • 35. About the absolute need to keep active research on the efficacy of direct-acting antiviral drugs against the hepatitis C virus.
    Pawlotsky JM
    J Hepatol; 2020 Oct; 73(4):752-754. PubMed ID: 32732060
    [No Abstract]   [Full Text] [Related]  

  • 36. Heading Toward the Elimination of Hepatitis C Virus.
    Kershenobich D; Torre-Delgadillo A; Aguilar-Valenzuela LM
    Rev Invest Clin; 2018; 70(1):29-31. PubMed ID: 29513300
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A pilot study to expand treatment of chronic hepatitis C in resource-limited settings.
    Mathur P; Comstock E; McSweegan E; Mercer N; Kumar NS; Kottilil S
    Antiviral Res; 2017 Oct; 146():184-190. PubMed ID: 28927676
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection.
    Sagnelli E; Pisaturo M; Martini S; Sagnelli C; Filippini P; Coppola N
    Expert Opin Pharmacother; 2014 Jul; 15(10):1337-49. PubMed ID: 24773464
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
    Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
    J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Selection of direct-acting antiviral agents for chronic hepatitis C infection].
    He YJ; Liu ZH; Hou JL
    Zhonghua Gan Zang Bing Za Zhi; 2018 Mar; 26(3):169-172. PubMed ID: 29804388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.